Kamada (KMDA) Scheduled to Post Earnings on Wednesday

Kamada (NASDAQ:KMDA) is scheduled to announce its earnings results before the market opens on Wednesday, May 8th. Analysts expect the company to announce earnings of $0.06 per share for the quarter. Kamada has set its FY 2024 guidance at EPS.Persons that are interested in registering for the company’s earnings conference call can do so using this link.

Kamada (NASDAQ:KMDA) last announced its quarterly earnings results on Wednesday, March 6th. The biotechnology company reported $0.09 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.05 by $0.04. Kamada had a net margin of 5.81% and a return on equity of 5.66%. The company had revenue of $36.43 million for the quarter, compared to the consensus estimate of $37.71 million. On average, analysts expect Kamada to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Kamada Price Performance

Shares of Kamada stock traded down $0.15 during trading hours on Tuesday, reaching $5.56. The company’s stock had a trading volume of 694 shares, compared to its average volume of 22,277. The firm has a 50 day moving average price of $5.59 and a 200-day moving average price of $5.50. The stock has a market cap of $319.59 million, a P/E ratio of 38.07 and a beta of 1.05. Kamada has a one year low of $4.08 and a one year high of $6.53.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating and set a $11.00 price objective on shares of Kamada in a report on Thursday, March 7th.

About Kamada

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.